Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIPE antisense RNA 1 (LIPE-AS1)
- Target
- LIPE-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Other (does not encode a protein)
01
Overview
LIPE-AS1 is a **long non-coding RNA (lncRNA)** encoded on the plus strand of human chromosome 19, transcribed antisense to the gene LIPE (encoding hormone-sensitive lipase), with conservation of gene structure and adipose tissue expression across human and mouse. LIPE-AS1 is highly expressed in subcutaneous and visceral adipose tissue, adrenal gland, testis, and mammary gland, correlating with the tissue distribution of LIPE itself. Functional studies show that knockdown of LIPE-AS1 variants can suppress adipogenesis and promote apoptosis in pre-adipocyte cell lines by downregulating adipogenic transcription factors (such as Pparg, Cebpa) and upregulating apoptosis markers. This suggests a regulatory role in protecting against stress during fat cell differentiation[2]. There is currently no evidence for its role as a therapeutic target, no reported drug ligands, nor established utility as a clinical biomarker.
- Other names
- LIPE antisense RNA 1LIPE-AS1
02
Mechanism of action
Not applicable, as there are no drugs reported to target this lncRNA.
03
Biological functions
Regulation of gene expression (especially of the overlapping LIPE gene)Adipogenesis and differentiation of adipocytesModulation of apoptosis during adipocyte differentiationPossibly regulation of cellular stress responsesGene expression regulation in adipose and related tissues
04
Disease associations
Other: Modulation of adipogenesis and apoptosis in adipose tissueNo direct association established with classical disease categories such as cancer, cardiovascular, neurodegenerative, or inflammatory disease as of the current literature
Beyond the preview
Go deeper on LIPE antisense RNA 1 (LIPE-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIPE antisense RNA 1 (LIPE-AS1).